KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Accounts Payables (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Accounts Payables data on record, last reported at $94.0 million in Q3 2025.

  • For Q3 2025, Accounts Payables fell 20.85% year-over-year to $94.0 million; the TTM value through Sep 2025 reached $94.0 million, down 20.85%, while the annual FY2024 figure was $214.4 million, 30.03% up from the prior year.
  • Accounts Payables reached $94.0 million in Q3 2025 per SRPT's latest filing, down from $136.7 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $214.4 million in Q4 2024 and bottomed at $44.2 million in Q3 2021.
  • Average Accounts Payables over 5 years is $104.6 million, with a median of $95.9 million recorded in 2022.
  • The widest YoY moves for Accounts Payables: up 188.22% in 2021, down 40.74% in 2021.
  • A 5-year view of Accounts Payables shows it stood at $76.7 million in 2021, then increased by 24.93% to $95.9 million in 2022, then soared by 72.01% to $164.9 million in 2023, then skyrocketed by 30.03% to $214.4 million in 2024, then crashed by 56.16% to $94.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $94.0 million in Q3 2025, $136.7 million in Q2 2025, and $156.1 million in Q1 2025.